| Topical intraocular pressure-lowering therapy is associated with poor patient adherence and troublesome side effects. |
| The slow-eluting travoprost intracameral implant produced clinically relevant and statistically significant greater intraocular pressure treatment effect than subjects’ pre-study topical prostaglandin analog monotherapy. |
| Superior intraocular pressure reduction with the intracameral implant is presumably due to improved patient adherence with an implant. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.